Promising new combo aims to improve remission in Tough-to-Treat leukemia
NCT ID NCT06928376
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study compares a new treatment (venetoclax plus CACAG) to the standard chemotherapy for adults newly diagnosed with intermediate- or high-risk acute myeloid leukemia (AML). About 160 participants aged 14 to 75 will be randomly assigned to one of the two groups. The main goal is to see if the new combination leads to a higher rate of complete remission after the first round of treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Chinese PLA General Hospital
RECRUITINGBeijing, Beijing Municipality, 100853, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a pill keep blood cancer at bay after a stem cell transplant?
- Could muscle loss predict blood cancer outcomes?
- Can a modified enzyme starve Hard-to-Treat blood cancers?
- Can a Low-Dose antifungal shield vulnerable patients from deadly fungal infections?
- Can a gentler chemo prep make stem cell transplants safer for blood cancer patients?
- Talking about the end: could guided conversations reduce futile cancer treatments?